Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13316059 | 0.84 | HSD11B1 (0.36) | ESR1CTSDBACE1HSD11B1MEN1 | |
| SCHEMBL13233322 | 0.80 | PDE10A (0.43) | ESR1CTSDBACE1MEN1ALDH1A1 | |
| SCHEMBL8276291 | 0.74 | ALDH1A1 (0.55) | ESR1MEN1ALDH1A1GAAMAPT | |
| SCHEMBL5714602 | 0.71 | ESR1 (0.34) | ESR1CTSDBACE1HSD11B1 | |
| SCHEMBL5713737 | 0.70 | MAOA (0.37) | ESR1CTSDBACE1MEN1KMT2A | |
| SCHEMBL19225688 | 0.70 | PDE10A (0.47) | ALDH1A1 | |
| SCHEMBL5714603 | 0.70 | ESR1 (0.33) | ESR1CTSDBACE1HSD11B1 | |
| SCHEMBL6337457 | 0.69 | CTSD (0.45) | ESR1CTSDBACE1HSD11B1MEN1 | |
| SCHEMBL19225665 | 0.68 | PKM (0.41) | KMT2A | |
| SCHEMBL8119522 | 0.68 | CTSD (0.44) | ESR1CTSDBACE1HSD11B1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | claimed |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | APP, DNPEP, BACE1 | ESR1 4782/4885CTSD 87/4885BACE1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.